Oral GLP-1 pill Wegovy is now available in the United States.

Novo Nordisk’s Wegovy pill is the first FDA‑approved oral GLP‑1 medicine for adults with obesity and is now widely available in the United States. The starting self-pay dose (1.5 mg) is listed at $149 per month.

Novo Nordisk has introduced Wegovy as a once-daily oral GLP-1 pill for weight loss in adults. It is the first oral GLP-1 medicine for obesity approved by the U.S. Food and Drug Administration and is now widely available across the United States. The pill was developed to mimic the appetite-regulating hormone effects associated with injectable GLP-1 treatments without the use of needles. Company representatives said some people had been waiting on the sidelines for a medicine that suited them. Key facts: - Wegovy is described as the first and only once-daily oral GLP-1 for weight loss in adults and has FDA approval. - The medicine is designed to reproduce appetite-regulating hormone effects similar to injectable GLP-1 treatments without needles. - The starting self-pay dose (1.5 mg) is listed at $149 per month, equivalent to about $5 per day as reported. - A four-milligram dose will be available at $149 per month through April 2026. - Novo Nordisk said the pill is now widely available across the United States. Summary: The approval and rollout introduce an oral option alongside existing injectable GLP-1 treatments for adults with obesity. Availability is nationwide in the United States, and a four-milligram dose is priced at $149 per month through April 2026.